Evidence map›Paper›PMID 26948919›Full record

Trial reportFuture oncology (London, England)2016

Quality of life in patients with metastatic breast cancer treated with metronomic chemotherapy.

Herman A Perroud, Carlos M Alasino, Maria J Rico, Francisco Queralt, Stella M Pezzotto, Viviana R Rozados, O Graciela Scharovsky

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Future oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Herman A PerroudExperimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.
Carlos M AlasinoInstitute of Oncology of Rosario, Rosario, Argentina.
Maria J RicoExperimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.
Francisco QueraltInstitute of Oncology of Rosario, Rosario, Argentina.
Stella M PezzottoInstitute of Immunology, School of Medical Sciences, National University of Rosario, Rosario, Argentina.
Viviana R RozadosExperimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.
O Graciela ScharovskyExperimental Oncology Section, Institute of Experimental Genetics, School of Medical Sciences, National University of Rosario, Rosario, Argentina.
National University of Rosario · ARInstituto de Oncología de Rosario · ARConsejo Nacional de Investigaciones Científicas y Técnicas · AR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThe objective of the study was to detect changes in quality of life (QoL) in metastatic breast cancer patients treated with metronomic chemotherapy with daily low doses of cyclophosphamide and celecoxib. MATERIAL &

methodsPatients included in a Phase II trial, treated with metronomic cyclophosphamide and celecoxib were included in the QoL study. Assessment of QoL was carried out every 2 months by the Functional Assessment of Cancer Therapy Breast (FACT-B) questionnaire, Brief Pain Inventory and Eastern Cooperative Oncologic Group scale. Data were analyzed at three time points: baseline (BL); middle of treatment (MT); and end of treatment (ET).

resultsA total of 20 patients were included. All patients were heavily pretreated. Treatment showed a good and safe therapeutic profile. With FACT-B questionnaire, no significant differences were observed during the response period (BL-MT). However, a significant increase was observed in the Emotional well-being and Additional concerns axes, when the last time point was included in the analysis (BL-MT-ET). A significant decrease in the proportion of patients with pain was found when comparing BL with ET (p = 0.046). The assessment with Eastern Cooperative Oncologic Group scale showed that 26.7% (4/15) of the patients improved their functional status and 40% (6/15) showed no changes, while 33.3% (5/10) worsened it.

conclusionPatients treated metronomically for several months did not worsen their QoL. A high proportion of patients showed improvement or no changes and there were less patients with pain at the end of the treatment.

Indexed as

Quality of LifeAdministration, MetronomicAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCancer PainCelecoxibCyclophosphamideFemaleHumansMiddle AgedSurveys and QuestionnairesTreatment OutcomeCelecoxibCyclophosphamidebreast cancerBrief Pain InventorycelecoxibcyclophosphamideECOGFACT-Bmetronomic chemotherapyquality of life

Identifiers

PMID26948919
PMCPMC4976839
OpenAlexW2294298046

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.